Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -685.80% is 3354% below its 1-year average of -19.86%, near the low end of its 1-year range (-685.80%–0.00%).
3353.69% below its 12-month average of -19.86%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-685.80%
NET PROFIT MARGIN AVG TTM
-19.86%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-3353.69%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-263669.23%
vs the sector median at left
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.47B
Net Profit Margin
-685.80%
TTM Avg
-19.86%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$1.45B
Net Profit Margin
6.59%
TTM Avg
2.75%
3Y Avg
2.46%
5Y Avg
3.07%
Market Cap
$1.48B
Net Profit Margin
6.57%
TTM Avg
5.15%
3Y Avg
3.47%
5Y Avg
4.27%
Market Cap
$1.45B
Net Profit Margin
-667.95%
TTM Avg
15.59%
3Y Avg
7.79%
5Y Avg
7.79%
Market Cap
$1.45B
Net Profit Margin
-16.75%
TTM Avg
-1.75%
3Y Avg
-3.69%
5Y Avg
-6.61%
Market Cap
$1.43B
Net Profit Margin
-81.79%
TTM Avg
-93.52%
3Y Avg
-130.36%
5Y Avg
-119.92%
Market Cap
$1.42B
Net Profit Margin
82.37%
TTM Avg
-82.37%
3Y Avg
-592.43%
5Y Avg
-414.63%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.47B | -685.80% | -19.86% | 0.00% | N/A |
| GH Research PLC (GHRS)vs › | $1.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 6.59% | 2.75% | 2.46% | 3.07% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 6.57% | 5.15% | 3.47% | 4.27% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | -667.95% | 15.59% | 7.79% | 7.79% |
| Certara, Inc. (CERT)vs › | $1.45B | -16.75% | -1.75% | -3.69% | -6.61% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | -81.79% | -93.52% | -130.36% | -119.92% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 82.37% | -82.37% | -592.43% | -414.63% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 12.02% | -7.78% | -15.24% | -11964.64% |
Operating Margin
0.0%
Net Profit Margin
-685.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | -99.28% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
